Navigation Links
CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
Date:8/19/2007

MARLBOROUGH, Mass., Aug. 1 /PRNewswire/ -- CardioFocus, Inc. announced today that it has been awarded CE Mark approval for its proprietary Endoscopic Ablation System. This novel transvenous device combines real-time, full color, endoscopic visualization and guidance with the delivery of therapeutic light energy to perform pulmonary vein isolation for the treatment of atrial fibrillation.

The Endoscopic Ablation System has been designed to treat the most common heart rhythm disturbance called atrial fibrillation, a disease affecting more than 5 million people in Europe and in the United States in addition to millions more worldwide. "We're very gratified to have achieved this level of confirmation for the work we have accomplished and the potential for aiding patients afflicted with atrial fibrillation worldwide," said Stephen Sagon the Company's President and CEO. "The CE Mark confirms our satisfaction of the EU medical device directives and assures patients and clinicians that our European clinical results and our manufacturing quality systems are of high caliber."

The CardioFocus Endoscopic Ablation System has also received US IDE approval for clinical investigation in a randomized, multi-center study, currently underway and enrolling patients at over a dozen leading medical centers across the country. Patients with symptomatic paroxysmal atrial fibrillation may learn about inclusion and exclusion criteria for the ENABLE trial, including information about participating centers at: http://www.clinicaltrials.gov/ct/show/NCT00477230?order=1

Study co-principal investigator Andrea Natale, MD of the Cleveland Clinic Foundation commented, "I am very satisfied with our ability to access anatomical targets and to achieve electrical isolation. The real-time view using the Endoscopic Ablation System provides a truly unique opportunity to tailor ablation therapy in a highly variable clinical setting." His colleague and study co-principal investigator Vivek Reddy of the Massachusetts General Hospital said, "Today, there are no devices specifically approved in the U.S. to treat this challenging arrhythmia. Multiple products are being used to pursue a variety of different strategies, but these are limited by the inability to directly visualize the tissue being ablated. The CardioFocus technique provides a new capability to directly address the difficult navigational challenges clinicians face in treating patients with symptomatic paroxysmal atrial fibrillation".

About Atrial Fibrillation

AF is a potentially serious cardiac arrhythmia typically requiring treatment for, rate and / or rhythm control as well as anticoagulation therapy to help contend with the elevated risk of stroke. In a recent statement issued by the Heart Rhythm Society, the European Heart Rhythm Association and the European Cardiac Arrhythmia Society, The Task Force on Catheter and Surgical Ablation of Atrial Fibrillation wrote: "There is a consensus among the Task Force that the primary indication for catheter AF ablation is the presence of symptomatic AF, refractory or intolerant to, at least one Class 1 or Class 3 antiarrhythmic medication". They further indicated that: a) ablation strategies that target the pulmonary veins (PV) and / or PV antrum are the cornerstone for most AF ablation procedures; b) if the PVs are targeted, complete electrical isolation should be the goal; and, c) careful identification of the PV ostia is mandatory to avoid ablation within the PVs.

About CardioFocus, Inc.

CardioFocus, Inc. is a venture-backed medical device company based in Marlborough, Massachusetts. The company is developing, manufacturing and investigating proprietary, disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias such as atrial fibrillation. For more information, visit http://www.cardiofocus.com.


'/>"/>
SOURCE CardioFocus, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. When Volume Matters, Immunoassay Systems Deliver
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. New Quality Control Systems for Every Laboratory Application
4. Immunoassay Systems - Your Laboratory Workhorse
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Researchers Discover Method for Identifying How Cancer Evades the Immune System
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
11. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 22, 2017  Applied BioMath ( ... to drug research and development, today announced the ... QSP Day 2017 is a day full of ... systems pharmacology (QSP) community. The focus is to ... de-risking and accelerating drug research and development. ...
(Date:3/22/2017)... MARLBOROUGH, Mass. , March 22, 2017 ... that it has completed the acquisition of Cynosure, Inc., ... $66 per share in cash. "We are ... forward to working with Michael Davin and ... in the large, rapidly growing medical aesthetics market," said ...
(Date:3/22/2017)... FinancialBuzz.com News Commentary ... to the significant development and innovation in EP technologies. ... the global electrophysiology market was worth $3.42 billion in ... 2022, with a GAGR of 13.4%. Electrophysiology is a ... heartbeats or arrhythmia. The report indicates that in addition ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... Intrinsic ... extensive therapeutic experience and operational excellence in oncology clinical trials, proudly announces today ... the treatment of non-small cell lung cancer and small cell lung cancer. , ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a Long ... Nassau County region, is embarking on a combined charity effort with the Great Neck ... the last 25 years, the Great Neck Breast Cancer Coalition has worked to support ...
(Date:3/22/2017)... ... March 22, 2017 , ... Schneider Insurance and Financial, a southern Montana firm ... Yellowstone Valley region, is launching a charity event aimed at raising local support for ... of Montana State, and is home to a broad variety of animals from all ...
(Date:3/22/2017)... ... 22, 2017 , ... Martin J. Mitchell Insurance, a Columbus ... throughout central Ohio, is initiating a charity drive to raise support for nearby ... and the Veteran's Brain Injury Center conclude that more than one in five ...
(Date:3/22/2017)... ... March 22, 2017 , ... HumanHaus is proud to ... The conventional broom was great when it was invented, but our customers today ... working parents, the social young couple, the empty nesters and retired that want to ...
Breaking Medicine News(10 mins):